Bendamustine in the treatment of multiple myeloma

Summary. Bendamustine is a cytotoxic agent which has properties of alkylating agents and purine analogues. Drug received a new birth and efficacy was proven in treatment of non- Hodgkin’s lymphoma, Hodgkin’s lymphoma and multiple myeloma. This article presents research that demonstrates the effectiveness of bendamustine as monotherapy and in combination with various drugs in primary multiple myeloma patients, in patients with relapsed or resistant to treatment.